[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"papillary-thyroid-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:papillary-thyroid-carcinoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,37,70,102,134,155,185,208,240,267,291,311,333,352],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100638949","clinical-utility-of-preoperative-thyroid-guidepx-testing-100638949",false,"NCT07584447","Clinical Utility of Preoperative Thyroid GuidePx® Testing","Inclusion Criteria:\n\n* Patients aged 18 years or older at the time of enrollment\n* English-speaking\n* Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)\n* Bethesda III or IV with ThyroSpec positive for BRAFV600E, TERT, rearrangements in BRAF, RET, NTRK1, NTRK3, RAS + TERT, RAS + EIF1AX, AKT1, PI3CA, CTNNB1, EGFR, rearrangements in ALK\n* Tumor 1- 4cm in size\n* No lymph node involvement on ultrasound\n* No gross extrathyroidal extension on ultrasound\n\nExclusion Criteria:\n\n* Prior thyroid operation\n* Distant metastatic disease\n* Personal history of thyroid cancer\n* History of whole-body radiation exposure or radiation to the head and neck region","ALL","18 Years",{"count":18,"type":19},85,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to learn whether having Thyroid GuidePx® test results available before treatment may help patients with papillary thyroid cancer and doctors make better-informed treatment decisions.",[23,24],"Papillary Thyroid Cancer","Papillary Thyroid Carcinoma","NOT_YET_RECRUITING","2026-05-28",{"date":28,"type":29},"2026-06-01","ACTUAL",{"date":31,"type":19},"2026-04",{"date":33,"type":19},"2029-04",{"name":35,"class":36},"University of Calgary","OTHER",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100585206","the-role-of-prophylactic-central-compartment-neck-dissection-in-the-management-of-2-to-4-cm-papillary-thyroid-carcinoma-100585206","NCT06899347","The Role of Prophylactic Central Compartment Neck Dissection in the Management of 2 to 4 cm Papillary Thyroid Carcinoma","Impact of PROphylactic Central cOMpArtment Neck Dissection for 2-4 cm Papillary Thyroid Carcinoma","PRO-COMAND","Inclusion criteria:\n\n1. PTC documented by fine needle aspiration cytology (FNAC) (TIR 4 or TIR 5 according to the Italian consensus for the classification and reporting of thyroid cytology \\[16\\]);\n2. patients scheduled for thyroid lobectomy or total thyroidectomy;\n3. no pre-operative evidence of lymph node metastases (cN0) at palpation and neck ultrasound (US);\n4. no clinical evidence of distant metastasis at diagnosis;\n5. age ≥ 18 years;\n6. signing informed consent.\n\nExclusion criteria:\n\n1. histotypes other than PTC;\n2. evidence of lymph node metastases during surgery even if not previously diagnosed;\n3. presence of distant metastasis;\n4. refusal to sign informed consent.\n\nExit criteria:\n\n1. withdrawal of informed consent;\n2. post-operative radioactive iodine therapy.",{"count":46,"type":19},392,"INTERVENTIONAL",[49],"NA","Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy and is frequently associated with microscopic central neck lymph node metastases, even in the absence of preoperative clinical evidence of nodal involvement (cN0). While prophylactic central compartment neck dissection (pCCND) may improve staging accuracy and potentially reduce disease persistence or recurrence, its routine use remains controversial due to the risk of increased surgical morbidity and potential negligible impact on oncologic outcomes.\n\nThis prospective randomized study aims to evaluate the oncological and surgical outcomes of cN0 PTC patients with tumors measuring 2 to 4 cm who undergo thyroid surgery with or without pCCND. Patients will be treated according to standard clinical practice with either total thyroidectomy (TT) or thyroid lobectomy (TL), and randomized to receive pCCND (bilateral or ipsilateral, respectively) or not. Patients undergoing TT and those undergoing TL will be analyzed separately in two parallel cohorts.\n\nThe primary objective is to assess the impact of pCCND on disease persistence or recurrence during long-term follow-up. Secondary objectives include evaluation of surgical complications and the impact of pCCND on pathological staging.",[24,52,53,54],"Central Compartment Neck Dissction","Thyroidectomy","Thyroid Lobectomy",[56,57,58,59,60,61],"papillary thyroid carcinoma","prophylactic central compartment neck dissection","thyroidectomy","surgical complications","outcomes","thyroid lobectomy","2026-04-28",{"date":64,"type":29},"2026-05-05",{"date":62,"type":19},{"date":67,"type":19},"2036-04",{"name":69,"class":36},"Leonardo Rossi",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":47,"phases":79,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100634186","decision-aid-efficacy-in-low-risk-thyroid-cancer-100634186","NCT07536412","Decision Aid Efficacy in Low Risk Thyroid Cancer","Efficacy of a Patient-facing Decision Aid in Reducing Decision Anxiety and Improving Decision Readiness in Low Risk Thyroid Cancer","Inclusion Criteria:\n\n* Low-risk thyroid cancer or thyroid nodule suspicious for malignancy\n* English-speaking\n\nExclusion Criteria:\n\n* Prior consultation with surgeon regarding the thyroid nodule \u002F cancer in question\n* Cancer\u002Fnodule has high risk features (e.g. extrathyroidal extension on ultrasound)\n* History of thyroid cancer\n* History of thyroid surgery\n* Currently pregnant (per patient report)",{"count":78,"type":19},34,[49],"Low-risk thyroid cancer grows very slowly. More than 99% of patients with this cancer survive for at least 5 years. There are 3 main treatment options: remove the whole thyroid, remove just the part of the thyroid with the cancer in it, or leave the cancer in the thyroid and monitor it. Survival is similar across the 3 main treatment options. It can be difficult for patients to choose a treatment option, especially when feeling anxious about the cancer diagnosis. In this study, enrolled patients will receive a decision aid after finding out they have cancer but before meeting a surgeon. This decision aid is a pamphlet. It gives information about the treatment options and a list of questions for patients to ask their surgeons at their clinic visit. The investigators will test whether this aid changes patient decision anxiety and decision readiness.",[82,83,24],"Differentiated Thyroid Cancer (DTC)","Papillary Thyroid Microcarcinoma",[85,86,87,88,89,90,91],"decision","decision aid","thyroid cancer","papillary thyroid microcarcinoma","decision readiness","decisional conflict","overtreatment","2026-04-11",{"date":94,"type":29},"2026-04-17",{"date":96,"type":19},"2026-05-15",{"date":98,"type":19},"2029-06-15",{"name":100,"class":36},"University of Maryland, Baltimore",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":47,"phases":113,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100633052","phase-2-sacituzumab-tirumotecan-in-recurrentmetastatic-adenoid-cystic-carcinoma-and-papillary-thyroid-carcinoma-strap-100633052","NCT07521670","Sacituzumab Tirumotecan in Recurrent\u002FMetastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)","A Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Patients With Recurrent\u002FMetastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP, ATLAS2501 NCCH2413\u002FMK016)","STRAP","Inclusion Criteria:\n\nCommon Eligibility Criteria for Cohorts A and B\n\n1. Unresectable locally advanced or recurrent\u002Fmetastatic adenoid cystic carcinoma or papillary thyroid carcinoma.\n2. Trophoblast cell-surface antigen 2 (TROP2) expression testing by immunohistochemistry or other methods is not required for enrollment. Provision of archival tumour tissue (where available) will be requested to support retrospective analysis. Waiver for tissue submission may be granted by the Steering Committee on a case-by-case basis if archival tissue is unavailable or insufficient for analysis.\n3. Age ≥18 years at the time of enrollment (≥21 years in Singapore)\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. At least one target lesion \\*identified on contrast-enhanced CT (head, neck, chest, abdomen, pelvis with ≤5 mm slice thickness) performed within 14 days prior to enrollment (same day of the week within 14 days is acceptable; this applies similarly to other time-based criteria below).\n\n   \\* A non-lymph node lesion with a longest diameter of ≥10 mm or a lymph node lesion with a short axis of ≥15 mm\n6. No prior treatment with Trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates or antibody-drug conjugates containing anti-topoisomerase I agents.\n7. Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or pre-treatment baseline level (except for alopecia and vitiligo). Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible.\n8. No administration of anticancer therapies (e.g., chemotherapy, targeted therapy, immunotherapy) within 13 days prior to enrollment.\n9. No major surgery under general anesthesia within 27 days prior to enrollment.\n10. No radiotherapy (including Gamma Knife or CyberKnife) within 13 days prior to enrollment. Thirteen days or fewer of palliative radiotherapy for non-CNS disease prior to enrollment is permitted. The last radiotherapy treatment must have been performed at least 7 days before enrollment.Two weeks or fewer of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.Two weeks or fewer of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.\n11. Laboratory values within the following criteria based on testing within 14 days prior to enrollment.\n\n    1. Neutrophil count≥1,500\u002Fmm3\n    2. Platelet count≥10x10\\^4\u002Fmm3\n    3. Hemoglobin≥9.0 g\u002FdL\n    4. AST\\\u003C100 U\u002FL\n    5. ALT\\\u003C100 U\u002FL\n    6. Total bilirubin\\\u003C1.5 mg\u002FdL\n    7. Creatinine\\\u003C1.5 mg\u002FdL, if \\>1.5 mg\u002FdL, estimated creatinine clearance ≥30 ml\u002Fmin. If an estimated value is used, it should be calculated using the Cockcroft-Gault formula.\n12. Peripheral oxygen saturation (SpO₂) ≥92% on room air within 14 days prior to enrollment.\n13. For male patients: Must agree to use acceptable contraception (refer to Notes 1,2,3) and refrain from sperm donation for at least 120 days after the last dose of study drug.\n\n    For female patients: Must not be pregnant or breastfeeding and must meet one of the following conditions:\n    1. Not of childbearing potential; or\n    2. If of childbearing potential:\n\n       * Agrees to use effective contraception (refer to Note 2) from the time of informed consent through at least 210 days after the last dose of study drug. If breastfeeding, agrees to discontinue breastfeeding from the first dose of the study drug through at least 10 days after the last dose.\n       * Uses a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with low user dependency, or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), as described in Appendix 19.3.2 of the study protocol during the intervention period and for at least the time needed to eliminate the study intervention after the last dose of study intervention. The participant agrees not to donate eggs (ova, oocytes) to others or freeze\u002Fstore eggs during this period for the purpose of reproduction. The length of time required to continue contraception for each study intervention is: sac-TMT: 210 days\n       * The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by POCBPs should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions are more stringent than the requirements above, the local label requirements are to be followed.\n       * Additional requirements for pregnancy testing during and after study intervention are in Appendix 19.3 of the study protocol\n       * Medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.\n\n    Note 1: The patient must not be currently pregnant and, when engaging in penile-vaginal intercourse with a partner who is capable of becoming pregnant, must use a condom (male or female type). In addition, because condoms may break or leak, the partner must also use an additional effective contraceptive method (see Appendix 19.3.3 of the study protocol).\n\n    Note 2: The use of contraception must comply with local regulations regarding contraceptive practices for clinical trial participants. If local labeling requirements related to study treatment are more stringent than the above, those local requirements must be followed.\n\n    Note 3: If the patient is confirmed to be azoospermic-either due to vasectomy or secondary to a medical condition-based on medical records, physical examination, or medical history as documented by site personnel, additional contraception is not required.\n14. Written informed consent obtained from the patient.\n\n    Cohort A-Specific Eligibility Criteria\n15. Diagnosis of adenoid cystic carcinoma of salivary gland origin confirmed by histological examination of the primary or metastatic lesion and the diagnosis has been confirmed by central pathology review, based on pathological images of the primary or metastatic lesion (including virtual slides or low- and high-power images of H\\&E-stained specimens).\n16. No history of receiving two or more lines of systemic anticancer therapy (excluding adjuvant therapy). Due to no standard care for these patients, patients without prior systemic therapy may also be included.\n17. Tumor growth has been observed within the past 6 months.\n\n    Cohort B-Specific Eligibility Criteria\n18. Diagnosis of PTC confirmed by histological examination of the primary or metastatic lesion. If this histological diagnosis was performed at the referring institution (i.e., a center not participating in the study), it must be reviewed and verified by a pathologist at the participating study site.\n19. Patients must have received at least one prior line of standard therapy for recurrent\u002Fmetastatic disease and no more than two prior lines (RAI therapy is not counted as a prior line).\n\nExclusion Criteria:\n\n1. Active central nervous system (CNS) metastases - including brain metastases, carcinomatous (leptomeningeal) meningitis, or symptomatic spinal metastases that require radiotherapy or surgical intervention. However, patients with previously treated brain metastases may be enrolled if imaging performed at screening shows radiographic stability for at least 28 days with no evidence of progression, they are clinically stable, and they have not required steroid therapy for at least 14 days before enrollment.\n2. Clinically significant pericardial effusion, pleural effusion, or ascites requiring treatment.\n3. Has a current and past history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing.\n4. Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \\>480 ms, prior treatment history with cardiotoxic agents and\u002For other serious cardiovascular and cerebrovascular diseases within 6 months before enrollment.\n5. Received a live or live-attenuated vaccine within 30 days before enrollment. Administration of inactivated vaccines are allowed.\n6. Is currently receiving a strong inducer\u002Finhibitor of CYP3A4 that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks.\n\n   Note: A list of strong inducers\u002Finhibitors of CYP3A4 can be found at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Please note that this list is not exhaustive and that investigators should review the locally-approved label for all concomitant therapy to ensure it is not a strong inducer\u002Finhibitor of CYP3A4.\n7. Is currently participating in another therapeutic clinical trial. Concurrent enrollment on another therapeutic clinical trial or any trial designed to impact the efficacy of anti-cancer therapy is prohibited.\n8. Has received an investigational agent or has used an investigational device within 28 days before enrollment.\n9. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding carcinoma in situ of the bladder) who have undergone potentially curative resection are not excluded.\n\n   Note: Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA \\\u003C10 ng\u002FmL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.\n10. Has an active infection requiring systemic therapy except those permitted in the exclusion criteria 15), 16), and 17) (e.g., HIV, HBV, HCV)\n11. Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the individual's ability to cooperate with the requirements of the study, or interfere with the individual's participation for the full duration of the study, such that it is not in the best interest of the individual to participate, in the opinion of the treating investigator.\n12. Severe hypersensitivity (Grades ≥3) to study intervention, any of their excipients, and\u002For to another biologic therapy.\n13. Has had major surgery or significant traumatic injury within 27 days before enrollment. Anticipation of the need for major surgery during the course of treatment with study intervention is also exclusionary.\n\n    Note: Participants who underwent major surgery must have adequately recovered from toxicity and\u002For complications from the surgery before starting study intervention.\n14. Has a history of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n15. Participants with HIV infection will be excluded unless all of the following conditions are met:\n\n    1. Having a CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening\n    2. Having achieved and maintained virologic suppression, defined as confirmed HIV RNA level below 50 or the LLOQ using the locally available assay, at the time of screening and for at least 12 weeks before screening\n    3. Absence of any AIDS-defining opportunistic infections within the past 12 months\n    4. Being on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before registration and agreeing to continue ART throughout the study Note: The ART regimen must not contain any antiretroviral medications that are strong CYP3A4 inducers\u002Finhibitors\u002Fsubstrates. Refer to https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Please note that this list is not exhaustive and that investigators should review the locally-approved label for all concomitant therapy to ensure it is not a strong inducer\u002Finhibitor\u002Fsubstrate of CYP3A4.\n16. Positive for HCV RNA, or, if HCV RNA is negative, has not completed curative antiviral therapy at least 28 days prior to enrollment. HCV RNA testing is required only for patients who test positive for HCV antibodies or as mandated by local regulations.\n17. Positive for HBs antigen, or negative for HBs antigen but positive for either HBs antibody or HBc antibody and positive for HBV DNA quantification. Patients are eligible if HBV DNA is below the lower limit of quantification; however, they will be excluded if they have not received at least 4 weeks of antiviral therapy prior to enrollment.\n18. Patients with active gastrointestinal ulcers.","99 Years",{"count":112,"type":19},68,[114],"PHASE2","This is an open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of Sacituzumab Tirumotecan (sac-TMT) monotherapy in patients with recurrent or metastatic adenoid cystic carcinoma (ACC) of salivary gland origin and papillary thyroid carcinoma (PTC). A total of 68 patients will be enrolled over in 18-month period, with 34 patients in Cohort A (ACC) and 34 in Cohort B (PTC). All participants will receive sac-TMT at a dose of 4 mg\u002Fkg administered intravenously on Days 1 and 15 of each 28-day cycle.\n\nThe primary endpoint is the objective response rate (ORR), defined as the proportion of patients achieving a complete or partial response as assessed by the site investigators. Secondary endpoints include progression-free survival, overall survival, disease control rate, safety and tolerability, dose intensity, and relative dose intensity.",[117,118,24],"Recurrent Adenoid Cystic Carcinoma","Adenoid Cystic Carcinoma Metastatic",[120,121,122,123,24],"Sacituzumab Tirumotecan","Recurrent","Metastatic","Adenoid Cystic Carcinoma","2026-04-07",{"date":126,"type":29},"2026-04-13",{"date":128,"type":19},"2026-05",{"date":130,"type":19},"2028-10-31",{"name":132,"class":36},"National Cancer Centre, Singapore",7,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":101},"100615954","multimodal-deep-learning-for-lymph-node-metastasis-in-thyroid-cancer-100615954","NCT07299318","Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer","A Multicenter Study on Developing a Multimodal Deep Learning Model Based on Color Doppler Ultrasound for Predicting Lymph Node Metastasis and Cancer Staging in Papillary Thyroid Carcinoma","Inclusion Criteria:\n\nCases aged 18-80 years who underwent thyroid ultrasound examination and postoperative pathological examination of the thyroid.\n\nCases with a first-time diagnosis of papillary thyroid carcinoma. Cases who underwent lymph node dissection\n\nExclusion Criteria:\n\nCases aged \\\u003C18 years or \\>80 years. Cases with poor-quality ultrasound images. Cases with incompletely visualized nodules. Cases with images showing multiple distinct lesions. Cases belonging to special populations. Cases with concurrent other tumors. Cases with a history of thyroid cancer resection","80 Years",{"count":143,"type":19},3200,"Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy in clinical practice, accounting for approximately 85% of all thyroid malignancies. The occurrence of cervical lymph node metastasis further increases the risk of local tumor recurrence and distant metastasis, thereby reducing patient survival rates. Pathological examinations reveal that approximately 30-80% of PTC patients have lymph node metastasis. Early detection of metastatic lymph nodes and the development of individualized treatment plans are crucial for improving patient prognosis. Currently, the primary method for diagnosing lymph node metastasis is ultrasound-guided fine-needle aspiration, but its accuracy is limited by sample quality and carries a risk of false-negative results. In recent years, deep learning technology has demonstrated significant potential in the field of medical image analysis. Therefore, the investigators aim to develop a deep learning model based on neck ultrasound to more accurately predict lymph node metastasis.",[24],"2025-12-22",{"date":148,"type":29},"2025-12-23",{"date":150,"type":19},"2026-01-01",{"date":152,"type":19},"2026-05-01",{"name":154,"class":36},"West China Hospital",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":15,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":47,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":101},"100616212","humanistic-continuing-care-via-wechat-for-patients-undergoing-thermal-ablation-of-papillary-thyroid-carcinoma-100616212","NCT07302672","Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n* Age 16-60 years; scheduled for thyroid thermal ablation\n* Papillary thyroid carcinoma (PTC)\n* Number of target lesions \\\u003C= 3\n* Largest lesion diameter \\\u003C= 2 cm; clinical stage T1N0M0 by imaging\n* Awake and able to cooperate under local anesthesia\n\nOwns a smartphone and can use WeChat\n\nExclusion Criteria:\n\n* Serious medical comorbidities or cognitive impairment that precludes participation\n* Prior thyroid surgery or thermal ablation\n* Unwilling or unable to join the WeChat group or complete postoperative follow-up","16 Years","60 Years",{"count":164,"type":19},108,[49],"The goal of this clinical trial is to test whether human-centered nursing care lowers emotional distress and improves quality of life for people who are awake during thyroid thermal ablation. The procedure uses local anesthesia, so participants remain awake and may feel tense. Human-centered care focuses on emotional support, clear communication, comfort, and follow-up, and it may improve the experience and recovery for patients.\n\nThe main questions are:\n\nDoes human-centered nursing care reduce emotional distress levels in patients undergoing thyroid thermal ablation?\n\nDoes human-centered nursing care improve patient quality of life after thyroid thermal ablation?\n\nIf there is a comparison group: Researchers will compare human-centered nursing care to usual nursing care to see if human-centered care leads to lower emotional distress and higher quality of life.\n\nParticipants will:\n\nReceive either human-centered nursing care or usual nursing care.\n\nComplete questionnaires before, during, and after the procedure to measure emotional distress, quality of life, pain, and satisfaction with care.\n\nHave their vital signs and quality of life tracked during and after the procedure.\n\nHave their adherence to care plans and any complications monitored.\n\nThe main outcomes are emotional distress levels and quality of life. Other outcomes include pain and vital signs during the procedure, satisfaction with care, and complication rates. Results may guide better care for people undergoing small, minimally invasive treatments while awake.",[24],[56,169,170,171,172,173,174],"thermal ablation","humanistic care","continuity care","Wechat","anxiety","quality of life","RECRUITING","2025-12-11",{"date":178,"type":29},"2025-12-24",{"date":180,"type":19},"2025-12-15",{"date":182,"type":19},"2026-12-31",{"name":184,"class":36},"Ming-an Yu",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":47,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":101},"100564008","comparative-study-of-transaxillary-robotic-thyroidectomy-with-mrnd-versus-conventional-open-surgery-in-n1b-ptc-100564008","NCT06623578","Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC","Comparative Study of Transaxillary Robotic Thyroidectomy With Modified Radical Neck Dissection Versus Conventional Open Surgery in Patients With Papillary Thyroid Carcinoma and Lateral Neck Node Metastases: a Prospective Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n* Age 18-70 years old, male or female;\n* papillary thyroid carcinoma with ipsilateral lateral cervical lymph node metastasis confirmed by FNAB;\n* thyroid tumor of less than 3.0 cm in the largest diameter;\n* lack of extrathyroidal extensions as estimated by preoperative ultrasonography and CT.\n\nExclusion Criteria:\n\n* level I or contralateral neck node metastases.\n* enlarged lymph node of larger than 2.0 cm in the short diameter.\n* suspected perinodal infiltration of metastatic lymph nodes.\n* cervical or\u002Fand thoracic deformity.\n* life-threatening diseases of liver, kidney, heart and other organs, or abnormal coagulation function.\n* clinical evidence of distant metastases such as in the lung, bone, and so on.\n* history of previous neck surgery and\u002For radiation therapy.\n* intolerable to general anesthesia\n* refuse either surgical procedure\n* unwilling to cooperate with long-term follow-up evaluation.","70 Years",{"count":194,"type":19},876,[49],"Thyroid cancer is one of the most common malignant tumors in women, ranking seventh in the United States and fourth in China. Papillary thyroid carcinoma is the most common pathological type (about 85% to 90% of thyroid cancers), and lateral cervical lymph node metastasis can reach 0.6-37.5% at diagnosis. For papillary thyroid cancer with lateral cervical lymph node metastasis, the 2015 ATA Guidelines in the United States recommend surgical resection and neck lymph node dissection as the primary treatment. Traditional cervical lymph node dissection often leaves obvious scars in the neck, which seriously affects the postoperative quality of life of patients. The previous studies have shown that endoscopy-assisted surgery with external cervical approach can achieve oncologic effects similar to traditional open surgery in the treatment of N1b papillary thyroid cancer, and can obtain better aesthetic results. However, endoscopic surgery still has some shortcomings, such as poor exposure of some surgical areas and difficult operation. Since November 2016, the investigators tried to apply modified transaxillary robotic-assisted surgery technology to the treatment of thyroid papillary carcinoma in China. The preliminary study included 30 patients, and the results showed that robot-assisted surgery via combined transaxillary-retroaural approach in the treatment of N1b papillary thyroid carcinoma achieved a good oncologic effect (5-year overall survival rate was 100.0%). As the surgical techniques improved, now the investigators can complete robotic-assisted lateral neck lymph node dissection via single-incision transaxillary approach. However, there is still a lack of high-quality evidence on the long-term oncologic outcome and quality of life of this procedure. In this study, a prospective, multi-center, randomized controlled study was conducted to compare the safety, long-term oncologic outcomes and postoperative quality of life of the robot-assisted surgery via single-incision transaxillary approach and open surgery in the treatment of N1b papillary thyroid cancer, which may provide an alternative for the patients with N1b papillary thyroid cancer.",[24,198],"Lymphatic Metastasis","2025-11-25",{"date":201,"type":29},"2025-12-03",{"date":203,"type":29},"2024-09-23",{"date":205,"type":19},"2033-12-31",{"name":207,"class":36},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":219,"conditions":220,"keywords":223,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":101},"100596248","ret-us-study---ultrasound-based-prediction-of-ret-alterations-and-lateral-neck-metastasis-in-thyroid-cancer-100596248","NCT07042984","RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer","RET-US Cohort: Prospective Evaluation of an AI-Ultrasound Model for Detecting RET Gene Alterations and Predicting Lateral Cervical Lymph-Node Metastasis in Papillary Thyroid Carcinoma","RET-US","Inclusion Criteria:\n\n* Age 18-75 years, able to provide written informed consent.\n* Pre-operative ultrasound findings highly suggestive of papillary thyroid carcinoma.\n* Planned thyroidectomy (any extent) at a participating institution.\n* Willing to undergo rapid 11-gene next-generation sequencing (NGS) panel and allow use of ultrasound DICOM images for AI analysis.\n\nExclusion Criteria:\n\n* Prior thyroid or major neck surgery.\n* Known medullary thyroid carcinoma, anaplastic carcinoma, or metastatic disease outside the neck.\n* Multiple endocrine neoplasia (MEN) syndromes or clinical suspicion of multi-gland disease.\n* Pregnant or breastfeeding.\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or other condition that precludes surgery or gene testing.","75 Years",{"count":218,"type":19},800,"Why is this study being done? RET gene alterations occur in only 5-10 % of papillary thyroid cancers, but they can change how surgeons treat the disease. Gene testing is costly and not always performed, so many RET-positive tumours are missed. Researchers have built a computer program (artificial-intelligence or \"AI\" model) that reads routine thyroid ultrasound images and predicts whether the tumour carries a RET alteration and whether the cancer has already spread to lymph-nodes in the side of the neck.\n\nWhat will happen in this study?\n\nAbout 800 adults who are scheduled for thyroid-cancer surgery will take part. Each participant will:\n\n* have a standard pre-operative ultrasound exam (no extra scanning time),\n* give a routine fine-needle sample for a 14-gene panel test (results in 24 h), and\n* allow the AI model to analyse the ultrasound images in the background. Doctors making treatment decisions will not see the AI result. After surgery, the research team will compare the AI predictions with the gene-panel result and the final pathology report.\n\nMain goal: To find out how accurately the AI model detects RET alterations. Secondary goals: To measure the model's ability to predict lymph-node spread, and to compare costs between ultrasound-only prediction and full gene testing.\n\nBenefits and risks: Participants will receive the current standard of care; there is no added risk beyond the usual ultrasound and needle biopsy. The study could lead to faster, less expensive ways to identify high-risk thyroid cancers in the future.",[24,221,222,198],"Thyroid Neoplasms","RET Proto-Oncogene Mutation",[224,225,226,227,228,229,230],"Ultrasound Radiomics","Artificial Intelligence","RET Fusion","BRAF V600E","Lateral Neck Metastasis","Deep Learning Model","11-Gene Panel","2025-06-21",{"date":233,"type":29},"2025-06-29",{"date":235,"type":19},"2025-07-01",{"date":237,"type":19},"2029-12-31",{"name":239,"class":36},"Fujian Medical University",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":15,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":47,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100590787","necessity-of-tsh-suppression-therapy-in-active-surveillance-for-thyroid-cancer-patients-100590787","NCT06971965","Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.","MAeSTro-TSH","Inclusion Criteria:\n\n* Thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.\n* Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype).\n* Non-pregnant women of childbearing potential (confirmed by medical history taking)\n\nExclusion Criteria:\n\n* Hyperthyroidism\n* If the investigator determines that you are not suitable for clinical research participation considering the following comorbidities:\n\n  * Myocardial infarction or cerebrovascular accident within the last three months.\n  * Diseases with limited life expectancy or potentially impairing the patient's ability to comply with at least five years of treatment or follow-up.","19 Years","79 Years",{"count":250,"type":19},578,[49],"This study is a multicenter randomized controlled trial conducted in Korea. A parallel, two-group randomized design will be with thyroid stimulating hormone suppression therapy group(low TSH group; intervention) is different from the wIthout thyroid stimulating hormone (TSH) suppression therapy group(high TSH group; control).",[254,24],"Thyroid Cancer",[256],"Active Surveillance","2025-05-07",{"date":259,"type":29},"2025-05-14",{"date":261,"type":19},"2025-06-02",{"date":263,"type":19},"2032-12-31",{"name":265,"class":266},"National Cancer Center, Korea","OTHER_GOV",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":47,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":4},"100572255","shared-decision-making-for-determining-treatment-strategies-in-low-risk-thyroid-cancer-100572255","NCT06730893","Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer","Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer: a Multicenter Cluster-Randomized Controlled Trial","MAeSTro-SDM","Inclusion Criteria:\n\n* Adults aged 18 years or older with a thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.\n* Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype).\n\nExclusion Criteria:\n\n* Patients who cannot undergo regular follow-up or are expected to have difficulties with follow-up.\n* Patients with indeterminate or benign findings on thyroid biopsy.",{"count":276,"type":19},310,[49],"This study is a multicenter cluster-randomized controlled trial conducted in Korea. A parallel, two-group cluster-randomized design will be used to test whether the Shared decision-making Group (SDM; intervention) is different from the Standard Care Group (SC; control).",[254,24],[281,282],"Active surveillance","Shared decision making","2025-04-27",{"date":285,"type":29},"2025-04-30",{"date":287,"type":19},"2025-05-12",{"date":289,"type":19},"2027-12-31",{"name":265,"class":266},{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":141,"enrollmentInfo":297,"targetDuration":299,"studyType":20,"phases":4,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":309,"locationsCount":4},"100571851","multiomics-study-of-biological-behavior-of-lymph-node-metastasis-in-papillary-thyroid-carcinoma-100571851","NCT06725628","Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n1. Pathological confirmation of PTC.\n2. Patients who underwent primary surgery accompanied by central neck lymph node dissection.\n3. Tumors measuring less than 2 cm in diameter.\n4. Postoperative pathological reports including detailed information on the number of lymph nodes dissected and the number of metastatic lymph nodes.\n5. Availability of comprehensive preoperative thyroid ultrasound images for analysis.\n\nExclusion Criteria:\n\n1. Postoperative pathological diagnosis indicating sub-types of PTC.\n2. Tumor invasion into adjacent anatomic structures such as the sternothyroid muscle, surrounding soft tissues, trachea, esophagus, or laryngeal nerve.\n3. History of neck trauma, previous tumor surgery, or adjuvant chemoradiotherapy.\n4. Fewer than three lymph nodes dissected during surgery.\n5. Concurrent acute inflammatory conditions or other hematologic disorders.",{"count":298,"type":19},2000,"5 Years","Establish a predictive model for assessing neck lymph node metastasis of papillary thyroid carcinoma based on metabolomics, proteomics, and imaging omics data, exploring an ideal protocal for the precise diagnosis and treatment of papillary thyroid carcinoma.\"",[24,302],"Lymph Node Cancer Metastatic","2024-12-04",{"date":305,"type":29},"2024-12-10",{"date":307,"type":19},"2024-12-01",{"date":307,"type":19},{"name":310,"class":266},"Tianhan Zhou",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":321,"conditions":322,"keywords":323,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":331,"locationsCount":4},"100564238","iodine-status-and-characteristics-of-papillary-thyroid-cancer-100564238","NCT06626581","Iodine Status and Characteristics of Papillary Thyroid Cancer","A Cross-sectional Study on Iodine Status and Characteristics of Papillary Thyroid Cancer","Inclusion Criteria:\n\n* Age range: 18\\~65 years old, gender not limited;\n* Living in the residential area for at least 5 years;\n* Patients diagnosed clinically with thyroid cancer and scheduled for thyroid surgery, with pathological diagnosis of papillary thyroid cancer;\n* Complete clinical data: including general information, relevant laboratory tests, pathological reports, surgical reports, ultrasound reports, etc.\n\nExclusion Criteria:\n\n* Pathological diagnosis of other types of thyroid cancer;\n* Diagnosed with other types of cancer;\n* There are serious comorbidities of the heart, liver, and kidneys;","65 Years",{"count":320,"type":19},600,"The effect of iodine on papillary thyroid cancer has been controversial for many years. The investigators designed a cross-sectional study and aimed to explore the relationship between the serum and urine iodine levels and the clinical and molecular characteristics of papillary thyroid cancer.",[24],[324,56],"iodine status","2024-10-03",{"date":327,"type":29},"2024-10-04",{"date":329,"type":19},"2024-11-01",{"date":182,"type":19},{"name":332,"class":266},"Shandong Provincial Hospital",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":192,"enrollmentInfo":340,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":101},"100561637","single-incision-gasless-endoscopic-total-thyroidectomy-via-subclavian-approach-versus-open-surgery-for-ptc-100561637","NCT06592755","Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTC","Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n* (1) thyroid neoplasm \\<3.0 cm;\n* (2) well differentiated papillary thyroid carcinoma.\n\nExclusion Criteria:\n\n* (1) extrathyroidal extensions estimated in ultrasonography scan;\n* (2) enlarged lymph nodes in lateral neck compartment on palpation, or US scan;\n* (3) suspected distant metastases;\n* (4) previous history of neck radiation therapy and\u002For surgery.",{"count":341,"type":19},120,"Historically, performing a contralateral thyroid lobectomy and lymph node dissection via the subclavian approach was considered challenging. This study aimed to evaluate the safety and feasibility of single-incision gasless endoscopic total thyroidectomy and central compartment neck dissection via the subclavian approach (SCA) in comparison to conventional open surgery for the treatment of papillary thyroid carcinoma (PTC) retrospectively.",[24],"2024-09-29",{"date":346,"type":29},"2024-10-01",{"date":348,"type":29},"2024-09-20",{"date":350,"type":19},"2024-09-30",{"name":207,"class":36},{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":358,"targetDuration":299,"studyType":20,"phases":4,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":101},"100513240","a-study-of-factors-influencing-recurrence-after-thermal-ablation-of-papillary-thyroid-carcinoma-100513240","NCT05962892","A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n①≥18 years old; ② Obtain informed consent; ③ Ultrasonography showed that malignant nodules were single, the maximum diameter of nodules was ≤1cm and the distance from the capsule was ≥2mm. ④ no lymph node metastasis or other extra-glandular metastasis in the neck; ⑤ PTC was confirmed by fine needle puncture pathology; ⑥ Patients who do not meet Article 3, who still strongly request thermal ablation while fully informing the patient of the risk of recurrence, and who have been clinically assessed to be technically capable of thermal ablation Exclusion Criteria:① Pregnant or lactating patients; ② Patients with other malignant tumors and not suitable for ablation by clinical evaluation; ③ Patients who cannot tolerate surgery; ④ Patients with cognitive impairment and other conditions who cannot accurately fill in thyroid-related questionnaires.",{"count":320,"type":19},"A prospective cohort of papillary thyroid carcinoma(PTC), patients who received thermal ablation in our hospital since February 2023 was established as the study object. Preoperative and postoperative demographic data, ultrasonography, other relevant laboratory tests, and thyroid disease-related scales such as fatigue, depression, and stress were collected. The influencing factors of PTC recurrence were analyzed.",[24,361],"Thermal Ablation",[24,363,361,364],"cohort","Recurrence","2024-01-29",{"date":367,"type":29},"2024-01-30",{"date":369,"type":19},"2024-02-01",{"date":371,"type":19},"2028-02-28",{"name":373,"class":36},"Beijing Friendship Hospital"]